Survey queries informed consent for genome editing clinical trials

By The Science Advisory Board staff writers

October 13, 2020 -- A new survey asked sickle cell disease patients, their parents, and physicians about what they want and need to know about genome editing in order to make an informed decision to participate in a clinical trial.

Researchers at the National Human Genome Research Institute (NHGRI), part of the U.S. National Institutes of Health, asked participants to complete a genetic literacy survey, watch an educational video about genome editing, complete a two-part survey, and take part in focus group discussions about CRISPR somatic genome editing, an experimental treatment option for sickle cell disease.

As genome-editing trials become more common, the process of informed consent is changing.
As genome-editing trials become more common, the process of informed consent is changing. Image courtesy of Ernesto del Aguila III, NHGRI.

"An important goal of informed consent is to facilitate decisions that are consistent with a person's values," said Sara Hull, PhD, director of the Bioethics Core at NHGRI, in a statement. "By talking to sickle cell disease stakeholders ahead of time, we can learn more about their values and hopefully do a better job of pinpointing what kinds of information will be most useful to potential research participants as they make very a difficult decision."

The researchers found that participants wanted to understand treatment side effects and the impact of somatic genome editing on quality of life. The focus groups expressed the need to have flexibility in the types of information they received, since people have differing levels of knowledge in biology and genomes.

Interestingly, while some physicians were concerned about the ability of their patients to understand concepts, sickle cell participants demonstrated higher genetic literacy levels than estimated.

The goal of informed consent for genome editing is ensuring the participant understands the aims of the trial; procedures, risks and benefits; sources of financial conflicts of interest; and researchers' affiliations. The study highlights the need to begin discussing what informed consent for somatic genomic editing looks like, amid lack of information and misconceptions about the risks and benefits of participating in a clinical trial.

"These first-in-human curative genome editing therapies are an opportunity to develop new consent approaches to meet the information needs of potential research study participants and their families," explained senior author Vence Bonham, JD, associate investigator in the Social and Behavioral Research Branch at NHGRI.

DIY vaccines are a landmine of public health concerns
A new Science article describes the legal and ethical implications of do-it-yourself (DIY) COVID-19 vaccines.
Modified CRISPR system aims to improve therapies for HIV, sickle cell disease
Researchers from City of Hope have improved the CRISPR-Cas9 system through novel sequence changes to the trans-activating RNA (tracrRNA). The improved...
NIH Invests $100 million in cures for sickle cell disease and HIV
The National Institutes of Health (HIH) announced that it plans to invest at least $100 million over the next four years towards developing affordable,...

Copyright © 2020

Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter